BLUE BELL, Pa.--(BUSINESS WIRE)--VGX Pharmaceuticals Inc. (VGX) and its affiliate, VGX Animal Health Inc. (VGXAH), announced today the publication in Molecular Therapy, the official journal of the American Society for Gene Therapy (http://www.nature.com/mt/index.html), of their work related to the Company’s leading Growth Hormone Releasing Hormone (GHRH) gene therapy product for the treatment of cancer-related anemia in companion dogs with spontaneous malignancies (Bodles-Brakhop et al., Double-blinded, Placebo-controlled Plasmid GHRH Trial for Cancer-associated Anemia in Dogs, Molecular Therapy, 2008, 16:862-870).
